Table 3 Comparison of characteristics, laboratory tests and tumor factors before treatment between patients with and without portosystemic collaterals (PSCs).
PSCs (−) (n = 13) | PSCs (+) (n = 10) | p value | |
|---|---|---|---|
Age* | 76 (64–84) | 72.5 (58–83) | 0.60 |
Gender (male/female) | 10/3 | 9/1 | 0.41 |
Performance status (0/1) | 12/1 | 9/1 | 0.85 |
Child-Pugh score (5/6) | 8/5 | 3/7 | 0.13 |
Total bilirubin (mg/dL)* | 0.6 (0.3–1.2) | 0.85 (0.7–1.7) | 0.004 |
Albumin (g/dL)* | 3.6 (2.9–4.8) | 3.5 (3–4.2) | 1.0 |
Prothrombin activity (%)* | 86 (73–100) | 76 (69–97) | 0.047 |
Aspartate aminotransferase (U/L)* | 29 (17–73) | 32 (23–73) | 0.38 |
Alanine aminotransferase (U/L)* | 19 (10–92) | 16.5 (12–51) | 0.82 |
Platelet count (×104/uL)* | 14.8 (7.5–31.1) | 11.3 (4.9–15.7) | 0.13 |
Alpha-fetoprotein (ng/mL)* | 9.6 (3.3–3992) | 1246 (24–236900) | 0.012 |
DCP (mAU/mL)* | 1142 (25–287990) | 1153 (16–64229) | 0.98 |
Ammonia level (µmol/L)* | 25 (10–45) | 50 (14–79) | 0.013 |
Intrahepatic tumor number (0/1/2–3/4≤) | 1/1/0/11 | 3/2/0/5 | 0.20 |
Main tumor size (mm)* | 30 (0–60) | 20 (0–140) | 0.76 |
Tumor size relative to the liver (<50%/50% ≤) | 12/1 | 10/0 | 0.37 |
Macro vascular invasion (yes/no) | 2/11 | 3/7 | 0.40 |
Extrahepatic metastasis (yes/no) | 6/7 | 6/4 | 0.51 |
TACE refractory (yes/no) | 8/5 | 3/7 | 0.13 |
HCC stage (II/III/IVa/IVb) | 3/3/2/5 | 2/1/1/6 | 0.74 |
Initial dose of lenvatinib (8 mg/12 mg) | 7/6 | 4/6 | 0.51 |
